TestoCore Hormonal Wellness in Delray Beach, FL, lists medical weight loss alongside hormone services, connecting two categories within a single business offering. For readers searching for “weight loss boca Raton Testocore,” the relevant business story is both specific and limited: a practice established around 2024 operates in Delray Beach, while national weight-loss spending figures provide context rather than proof of local demand.

A Delray Beach Business Built Around Weight and Hormone Services

TestoCore Hormonal Wellness identifies its address as 4733 W Atlantic Ave Suite C8, Delray Beach, FL 33445. Its description, “Rebalance your life, one hormone at the time,” places hormones at the center of its public identity. The approximately 2024 establishment date provides a basic timeline, but not a record of expansion, patient volume or financial performance. Those distinctions matter in a business profile: a founding date establishes when an enterprise began, not how quickly it has grown or how much of a surrounding market it serves. Similarly, its Delray Beach address is a verified location, not evidence of a separate Boca Raton office. The connection to Boca Raton in this article is the search context, rather than a claim that the business maintains premises there.

The listed offerings are Medical Weight Loss, Semaglutide, Tirzepatide, Hormone Therapy for Men, Hormone Therapy for Women, Bio-identical Hormone Replacement Therapy, Testosterone Therapy and Menopause Treatment. That combination describes the breadth of the published service menu without establishing how any individual service is delivered. It also makes the business more specific than a weight-loss-only listing: hormone-related services are part of its stated offering, not an unrelated category added for comparison. The available business facts do not establish treatment prices, appointment frequency, prescribing criteria or the relationship between particular services. Accordingly, the menu is evidence of what TestoCore names as available categories, not evidence that every patient receives multiple treatments or follows the same course.

Boca Raton Searches Meet a National Market Moving in Different Directions

The national context is substantial, but its boundaries are important. Marketdata LLC, in its report titled “U.S. Weight Loss Market Worth $135 Billion, To Grow 6.6% in 2026,” estimates that the U.S. weight-loss market, including health clubs, reached $135 billion in 2025 and forecasts 6.6% growth in 2026. The same source reports that commercial weight-loss companies’ combined revenue fell 24% to $1.86 billion in 2025. These are Marketdata estimates, not government statistics, and the forecast is not a realized result. Taken together, they describe a broad market and a narrower business category moving differently, rather than a uniform expansion benefiting every provider. The commercial-company revenue figure should not be treated as a financial benchmark for TestoCore. For independent economic context, the U.S. Census Bureau’s Business & Economy resources offer a separate reference point for business research; they are not the source of the Marketdata figures cited here.

For Delray Beach and Boca Raton, the central analytical issue is the gap between a national category and a local business opportunity. No current market size or growth rate specifically for weight-loss services in either city was verified for this article. It would therefore be unsupported to assign either city the national growth forecast, calculate TestoCore’s market share or describe its revenue trajectory. The inclusion of health clubs in the $135 billion estimate also means that total cannot be read as spending solely on medical weight loss. Likewise, a decline in commercial weight-loss-company revenue does not establish a decline in a Delray Beach practice’s business. Researchers seeking employment context can consult U.S. Bureau of Labor Statistics employment resources, but no local employment count is asserted here. For a reader comparing nearby services, the useful distinction is between a documented local offering and an unmeasured local market: TestoCore’s service list supports the former, while national spending alone cannot establish the latter.

Semaglutide and Tirzepatide Within TestoCore’s Published Offering

TestoCore’s weight-related listing includes Medical Weight Loss, Semaglutide and Tirzepatide. Its hormone-related listing includes Hormone Therapy for Men, Hormone Therapy for Women, Bio-identical Hormone Replacement Therapy, Testosterone Therapy and Menopause Treatment. These are the named services on which a factual description of the business can rest. The list identifies categories and named treatments, but supplies no basis for claims about comparative effectiveness, individual suitability, guaranteed results or treatment duration. Nor does the presence of weight-loss and hormone services on the same menu establish that one is required to obtain the other. The neutral description is therefore straightforward: TestoCore Hormonal Wellness publishes both medical weight-loss and hormone-related offerings at its Delray Beach business. Its service names should remain distinct from conclusions about patient outcomes, business scale or clinical arrangements that the supplied facts do not establish.

For readers considering the Delray Beach business in connection with a Boca Raton weight-loss search, the documented picture is a practice established around 2024 with a menu spanning medical weight loss and hormone services. The wider market provides a business backdrop, but not a local growth claim or an endorsement of an individual treatment. Keeping those levels separate makes the information useful without presenting a national forecast as evidence of TestoCore’s performance. The business lists its offerings at testocorehrt.com.

Further reading from The Capital Front: Live Well Clinic Places Medical Weight Loss in Bentonville's Broader Wellness Conversation and The Clarity Way MD Places Weight Loss Within a Broader Wellness Offering.